Orkla Food Ingredients signs licence agreement with Renaissance BioScience Corp. for Acrylamide-Reducing Yeast Technology

OSLO, Norway and VANCOUVER, British Columbia, May 23, 2017 (GLOBE NEWSWIRE) -- Orkla Food Ingredients, a business area of Orkla ASA (OSE:ORK) has signed a licence agreement with Renaissance BioScience Corp. to exclusively produce and sell Renaissance acrylamide-reducing yeast to food manufacturers in the European Nordic and Baltic markets, starting in Q3 2017. “Renaissance’s … [Read more...]

Rheumatology Leaders Oppose Sweeping Healthcare Cuts in Trump Administration Budget

Atlanta, May 23, 2017 (GLOBE NEWSWIRE) -- ATLANTA – The American College of Rheumatology (ACR) today expressed opposition to the Trump Administration’s proposed budget cuts to federal programs and institutions that provide critical resources in the fight against rheumatic diseases, including the National Institutes of Health (NIH), the U.S. Food and Drug Administration (FDA), … [Read more...]

Syndax Announces Proposed Public Offering of Common Stock

WALTHAM, Mass., May 23, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX) announced today that it plans to offer and sell, subject to market and other conditions, $50 million of its common stock in an underwritten public offering. There can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering. … [Read more...]

Retrophin to Present at the Jefferies 2017 Global Healthcare Conference

SAN DIEGO, May 23, 2017 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ:RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2017 Global Healthcare Conference in New York City on Tuesday, June 6, 2017 at 3:30 p.m. ET. A live webcast of the presentation will be available at http://ir.retrophin.com/events.cfm and an archived replay … [Read more...]

Plazomicin Granted FDA Breakthrough Therapy Designation

SOUTH SAN FRANCISCO, Calif., May 23, 2017 (GLOBE NEWSWIRE) -- Achaogen, Inc. (NASDAQ:AKAO), a late-stage biopharmaceutical company developing innovative antibacterials addressing multi-drug resistant (MDR) gram-negative infections, today announced that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy designation for plazomicin, Achaogen’s lead product … [Read more...]